Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)
Chronic Pain, Widespread
About this trial
This is an interventional treatment trial for Chronic Pain, Widespread
Eligibility Criteria
Inclusion criteria:
- Age between 18-50 yrs.
- History of cannabis use.
- Chronic musculoskeletal and joint pain for at least 3 months or longer.
- Participants must live within a 60 mile radius of Salt Lake City, Utah to be eligible.
Exclusion criteria:
- Current or past neurological illness.
- Substance abuse or dependence within the prior 60 days.
- Contraindication to brain MRI.
- Type I and type II diabetes.
- Unstable medical conditions.
- Consumption of more than 2 drinks of alcohol per night.
- Current pregnancy or planning to become pregnant or breastfeeding
- History of seizures or head trauma
- Active or history of major mental illness
- LFT results 3 times greater than the upper limit of normal at screening.
- Participants may be excluded if the PI feels they do not meet safety criteria.
Sites / Locations
- University Of UtahRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Placebo Comparator
Delta-9-Tetrahydrocannabinol's (Delta-9-THC) effects on pain
Cannabidiol's (CBD) effects on pain
Placebo
This arm will be testing the analgesic effects of orally dosed Delta-9-Tetrahydrocannabinol on subjects with chronic non-cancer pain.
This arm will be testing the analgesic effects of orally dosed Cannabidiol on subjects with chronic non-cancer pain.
This Placebo arm will act as the control as standard of care medications will be continued through the study. This arm will allow us to compare the analgesic effects of the other two arms with the standard of care treatments for chronic non-cancer pain.